25985 Efficacy of tildrakizumab 100 mg for PASI improvement in patients with moderate to severe plaque psoriasis: Pooled analysis using nonresponder imputation from reSURFACE 1 and 2 through week 52

2021 ◽  
Vol 85 (3) ◽  
pp. AB78
Author(s):  
Mark G. Lebwohl ◽  
Richard G.B. Langley ◽  
Rodney Sinclair ◽  
April W. Armstrong ◽  
Alan M. Mendelsohn ◽  
...  
2017 ◽  
Vol 34 (6) ◽  
pp. 1327-1339 ◽  
Author(s):  
Sandra Adsit ◽  
Enrique Rivas Zaldivar ◽  
Howard Sofen ◽  
Ignacio Dei-Cas ◽  
César Maldonado-García ◽  
...  

2016 ◽  
Vol 75 (1) ◽  
pp. 83-98.e4 ◽  
Author(s):  
Peter C.M. van de Kerkhof ◽  
Christopher E.M. Griffiths ◽  
Kristian Reich ◽  
Craig L. Leonardi ◽  
Andrew Blauvelt ◽  
...  

2018 ◽  
Vol 2 ◽  
pp. S19
Author(s):  
A Blauvelt ◽  
A Armstrong ◽  
P Rich ◽  
R Kisa ◽  
A Guana ◽  
...  

Abstract not available. Disclosures: Study sponsored by Novartis. Copyright 2018 SKIN


2020 ◽  
Vol 19 (8) ◽  
pp. 747-754
Author(s):  
Fran Cook-Bolden ◽  
Adelaide Hebert ◽  
Scott Guenthner ◽  
Robert Kang ◽  
Gina Martin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document